Trusted Research Environment: revolutionizing pharma’s drug development with RWD

Executive summary

In today’s fast-moving pharmaceutical landscape, secure, diverse, and global access to high-quality data is essential for efficient and successful drug development. Traditional clinical trials face well-known challenges such as high costs, long timelines, and limited patient diversity. To address these, BC Platforms has introduced the Trusted Research Environment (TRE), a federated analytics platform that harnesses Real-World Data (RWD) to transform how life sciences organizations collaborate, innovate, and accelerate discovery. Our platform now connects data from more than 130 million patient lives across six continents — North America, South America, Europe, Africa, Asia, and Australia.

Unlocking the power of Real-World Data

Real-world data (RWD) refers to data collected from everyday healthcare interactions rather than controlled clinical trials. It includes information from electronic health records (EHRs), claims and billing data, imaging (DICOM) and omics data, patient-reported outcomes (PROs), and data from wearables or registries. RWD helps researchers understand how drugs perform in real-world settings, offering a more complete picture of efficacy, safety, and outcomes. BC Platforms’ Trusted Research Environment enables pharma companies to use these insights while maintaining strict adherence to global privacy regulations, including GDPR, HIPAA, and ISO standards.

What makes the Trusted Research Environment different?

The TRE is an advanced cloud-based federated platform that brings together pharmaceutical companies, academic institutions, research organizations, biobanks, and healthcare providers. It integrates multi-omic and multi-modal datasets — genomic, clinical, imaging, and more — to give a 360° view of patients’ real-world experiences without moving or duplicating data.

Key benefits of BC Platforms’ TRE in drug development

Enhanced study design and recruitment

By incorporating real-world evidence, the TRE allows for robust clinical study design and targeted patient recruitment across diverse global populations, reducing trial time and cost.

Improved safety and efficacy assessment

Researchers can evaluate drug performance across broader patient groups, including those with comorbidities and demographic differences, for a clearer understanding of real-world safety and effectiveness.

Accelerated time-to-market

Access to harmonized, high-quality RWD enables faster biomarker discovery, cohort identification, and data-driven decision-making, helping new treatments reach patients sooner.

Secure collaboration and data sharing

The TRE enables privacy-preserving collaboration among global stakeholders, facilitating insights without data movement or copies. This federated model promotes transparency, innovation, and trust.

From data to discovery

BC Platforms’ Trusted Research Environment is revolutionizing pharma’s approach to drug development by combining real-world evidence, advanced analytics, and secure collaboration to deliver faster, safer, and more effective therapies. Together with our Data Partners, we have the data you didn’t think you could find, empowering precision research and driving innovation worldwide.

Learn more

• Facilitating data-driven partnerships across the pharma and biotech community through Trusted Collaboration Environments
• Sciences Insights video: Trusted Collaboration Environment (TCE) – Powerful Real World Data sharing across borders
• Watch the Evidence Base Expert Interview with Mark Heffernan on Trusted Collaboration Environments